Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus CETIRIZINE HYDROCHLORIDE ALLERGY.
BENADRYL vs CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Category C
Category A/B
Antihistamine
Antihistamine